Theraligen, 5 mg 100 pcs

Pharmacotherapeutic group

Anxiolytic medicine. Sedative

ATH Code

R06AD

Pharmacodynamics:

It is a phenothiazine derivative.

Alimazine acts as a mild sedative and anti-anxiety drug has a positive effect on obsessive compulsive disorder and phobia.

It is used in psychosomatic manifestations developing due to neurovegetative disorders vascular traumatic and infectious disorders of the central nervous system. The sedative effect promotes normalization of sleep in patients in this category.

It has antiemetic and anti-cough activity.

Sedative and anxiolytic effects are caused by blockade of adrenoreceptors of reticular formation of the brain stem. Antiemetic and vegetative-stabilizing action is caused by blockade of dopamine D2-receptors of trigger zone of the vomiting center.

Because of its antihistamine activity, alimemazine is used in allergic diseases especially of the respiratory tract and in itching of the skin.

Alimemazine is more active in antihistamine and sedative action than diprazine. The antipruritic action is due to its effect on type 1 histamine receptors.

Pharmacokinetics:

It is rapidly and completely absorbed by all routes of administration. The action of alimazine begins 15-20 minutes after administration and lasts 6-8 hours. Binding with plasma proteins is 20-30%. It is metabolized in the liver. Excreted by the kidneys – 70-80% as a metabolite (sulfoxide).

Indications

In adults and children from 7 years:

As sedative (sedative), anti-anxiety and sleep aid: organic anxiety disorder (r-in) (mono or combined therapy); in combination therapy: dementia, schizophrenia (when neurosis-like disorders predominate), affective r-va, generalized anxiety r-va, obsessive-compulsive r-va, reaction to severe stress and adaptation disorders, dissociative (conversion) r-va, somatoform disorders with severe anxiety or ineffectiveness of standard therapy, unspecified autonomic nervous system (ANS) disorders, other autonomic nervous system (ANS) disorders, anorexia nervosa, emotionally unstable personality disorders (impulsive and borderline types), hysterical personality disorders, anxious personality disorders, Enduring personality change after experiencing a disaster, hyperkinetic r-e-behavior, family-centered r-e-behavior, unsocialized r-e-behavior, anxiety, agitation, and other symptoms and signs related to the emotional state, other neurotic r-va (neurasthenia, unspecified neurotic r-va), insomnia of inorganic etiology, emotional r-va whose onset is specific to childhood (phobic, social, unspecified emotional, other emotional r-va in childhood. As an anti-allergic agent: itching, regardless of location and etiology, asthma, pollinosis, whooping cough, unspecified allergies.

In children from 3 years old:

As an antiallergic agent:Itching regardless of location or etiology (itching in photocontact dermatitis and solar urticaria, dermatitis, eczema, urticaria, bites or stings from nonvenomous insects or arthropods, chickenpox, measles, Hodgkin’s disease, diabetes, shingles, itching anus, vulva, unspecified anogenital) as monotherapy or as part of combination therapy. As a sedative (sedative): in drug preparation for surgery (with the purpose of sedation before surgery).

Active ingredient

Composition

One tablet contains:

the active ingredient:

alimazine tartrate – 5.0 mg;

excipients: lactose monohydrate, microcrystalline cellulose, pregelatinized starch, colloidal silica (aerosil), croscarmellose sodium, magnesium stearate.

Shell composition: Opadray II 85F34655: partially hydrolyzed polyvinyl alcohol, macrogol-3350, talc, titanium dioxide E 171, carmine red dye E 120, sunset yellow aluminum varnish E 110, indigo carmine aluminum varnish E 132.

How to take, the dosage

Intravenously, without chewing.

Adults:

Course treatment should be started with 2.5-5 mg in the evening with a gradual increase in the daily dose to the desired effect. The daily dose may be divided into 3-4 doses. The duration of treatment may be 2 to 6 months or more and is determined by the physician. To achieve: vegetative stabilizing effect – 15-60 mg/day, anxiolytic effect – 20-80 mg/day, sedative and/or hypnotic effect – 5-10 mg/day once (20-30 min before sleep), for symptomatic treatment of allergic reactions – 10-40 mg/day. The maximum dose for adults is 500 mg/day, for persons older than 60 years – 200 mg/day.

Children from 7 years (depending on age and body weight):to achieve anxiolytic effect – 20-40 mg/day. The course of treatment should be started with 2.5-5 mg with a gradual increase in the daily dose to the desired effect. The daily dose may be divided into 3-4 doses. To achieve a sedative and/or hypnotic effect, 2.5-5 mg once (20-30 min before sleep), to achieve a sedative effect in behavioral disorders in psychotic states, it is possible to increase the daily dose to 60 mg/day. For symptomatic treatment of allergic reactions, 5-20 mg/day. The duration of the course of treatment may be from 2 to 6 months or more and is determined by the physician.

Children from 3 years:

For symptomatic treatment of allergic reactions, 2.5-5 mg 3-4 times/day. The duration of the course of treatment may be from 2 to 6 months or more and is determined by the physician. For sedation before surgery, 2 mg/kg 2 to 2 hours before surgery is prescribed for children aged 3 to 7 years. The maximum daily dose is 2 mg/kg.

Interaction

Enhances the effects of narcotic analgesics, hypnotics, anxiolytics and antipsychotics, as well as drugs for general anesthesia, m-cholinoblockers and hypotensive drugs. When using: with antiepileptic drugs and barbiturates there is a decrease of the seizure activity threshold, with β-blockers there may be a marked decrease in BP, arrhythmia, with MAO inhibitors or phenothiazine derivatives there is an increased risk of arterial hypotension and extrapyramidal disorders.List of all interactions with other drugs is presented in the instructions for medical use.

Special Instructions

Contraindications

Hypersensitivity, lactose intolerance, lactase deficiency, glucose-galactose malabsorption, closed-angle glaucoma, prostatic hyperplasia, severe hepatic and/or renal failure, parkinsonism, myasthenia, Reye syndrome, concomitant use of MAO inhibitors, pregnancy and lactation, children under 3 years of age when used as an anti-allergic agent and for sedation before surgery, under 7 years for other indications.

Side effects

Side effects are extremely rare and expressed insignificantly. Nervous system disorders: somnolence, lethargy, rapid fatigability (occurs mainly during the first days of use and rarely requires drug withdrawal), paradoxical reactions (anxiety, agitation, nightmares, irritability), confusion, extrapyramidal disorders. Sensory organs: blurred vision, tinnitus or ringing in the ears. Cardiovascular system: dizziness, decreased blood pressure, tachycardia. Allergic reactions, muscle relaxation. List of all side effects is presented in the instructions for medical use.